Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19164342 | 0.89 | NPC1 (0.53) | NPC1RAB9AMAPTSMN1; SMN2EPHX1 | |
| SCHEMBL19171376 | 0.89 | EPHX1 (0.57) | NPC1RAB9AMAPTSMN1; SMN2EPHX1 | |
| SCHEMBL19171900 | 0.86 | EPHX1 (0.60) | NPC1RAB9AMAPTSMN1; SMN2EPHX1 | |
| SCHEMBL19171947 | 0.86 | EPHX1 (0.60) | NPC1RAB9AMAPTSMN1; SMN2EPHX1 | |
| SCHEMBL3512598 | 0.86 | NPC1 (0.52) | NPC1RAB9AMAPTSMN1; SMN2EPHX1 | |
| SCHEMBL19171880 | 0.84 | EPHX1 (0.53) | NPC1RAB9AMAPTSMN1; SMN2EPHX1 | |
| SCHEMBL19171338 | 0.84 | NPC1 (0.57) | NPC1RAB9AMAPTSMN1; SMN2EPHX1 | |
| SCHEMBL3514860 | 0.83 | NPC1 (0.49) | NPC1RAB9AMAPTSMN1; SMN2EPHX1 | |
| SCHEMBL9660162 | 0.83 | EPHX1 (0.61) | NPC1RAB9AMAPTSMN1; SMN2EPHX1 | |
| SCHEMBL20017302 | 0.81 | NPC1 (0.55) | NPC1RAB9AMAPTSMN1; SMN2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | CAPRARO HANS-GEORG | 2010-12-02 | — | — | US | disclosed |
| EP-2155753-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008138834-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | PI4KA, PIK3CA, PIK3CB | NPC1 1148/4885RAB9A 1851/4885MAPT 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.